Reported Earlier, BeiGene Secures Global Licensing Agreement For Novel MAT2A Inhibitor SYH2039 To Target MTAP-Deleted Solid Tumors
Reported Earlier, BeiGene Secures Global Licensing Agreement For Novel MAT2A Inhibitor SYH2039 To Target MTAP-Deleted Solid Tumors
SYH2039 targets solid tumors that have a mutation called MTAP deletion, which is estimated to be present in approximately 15 percent of all cancer types with the most common including glioblastoma, pancreatic cancer and non-small cell lung cancer.
SYH2039针对具有MTAP缺失突变的实体肿瘤，预计该突变存在于大约15%的所有癌症类型中，最常见的包括胶质母细胞瘤、胰腺癌和非小细胞肺癌。
"With one of the most dynamic solid tumor portfolios in the industry, we are continually assessing opportunities that align with our strategic focus and address significant unmet needs for patients. This MAT2A inhibitor is a valuable addition to our solid tumor pipeline, and we're eager to explore its potential, particularly in combination with our internally developed PRMT5 inhibitor, BGB-58067. Together, these assets hold promise for advancing treatment across a range of solid tumors," said Lai Wang, Ph.D., Global Head of R&D at BeiGene.
"我们在行业中拥有最具活力的实体肿瘤产品组合之一，我们不断评估与我们的战略重点对齐并解决患者重大未满足需求的机会。这种MAT2A抑制剂是我们实体肿瘤管线的宝贵补充，我们渴望探索其潜力，特别是与我们内部开发的PRMT5抑制剂BGb-58067联合使用。综合来看，这些资产有望推动治疗跨越多个实体肿瘤区间,"百济神州研发全球负责人Lai Wang博士表示。